Updated as of September 22, 2021

Please refer to local prescribing information for more information, including full safety information, on Incyte’s marketed medicines, or on medicines marketed by Incyte’s collaboration partners.

1. Jakafi marketed by Incyte in the U.S.; ruxolitinib licensed to Novartis outside the U.S. 2. Approved in the U.S. 3. Approved in multiple territories, including the U.S., Canada, Europe, and Japan 4. Development in collaboration with MorphoSys and co-commercialization in the U.S. with MorphoSys; exclusive commercialization rights held by Incyte outside the U.S. 5. Approved in Europe 6. Approved in Canada 7. European rights to Iclusig licensed from Takeda 8. In collaboration with MacroGenics 9. Exclusive development and commercialization rights held by Incyte outside the U.S., by Merus in the U.S. 10. Licensed from Calithera 11. Discovery collaboration with Agenus 12. Worldwide rights to baricitinib licensed to Lilly 13. Approved in multiple territories globally 14. Worldwide rights to capmatinib licensed to Novartis 15. Approved in the U.S. and Japan 
16. Authorized in the U.S. for use under an EUA, for treatment of COVID-19 in certain hospitalized patients. 
EUA, Emergency Use Authorization; FGFR, fibroblast growth factor receptor; GVHD, graft-versus-host disease; MF, myelofibrosis; MLN, myeloid/lymphoid neoplasms; MSI-H, microsatellite instability-high; NSCLC, non-small cell lung cancer; Ph+, Philadelphia chromosome-positive.